Affinage

TRIM37

E3 ubiquitin-protein ligase TRIM37 · UniProt O94972

Length
964 aa
Mass
107.9 kDa
Annotated
2026-06-10
100 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRIM37 is a RING-domain E3 ubiquitin ligase whose catalytic activity is essential for its diverse cellular roles, abolished by RING mutation and by disease-associated point mutations (PMID:15885686). Through monoubiquitination of histone H2A, it acts as a transcriptional repressor that cooperates with PRC1 and PRC2 to co-occupy and silence target promoters, including tumor suppressor genes in 17q23-amplified breast cancer (PMID:25470042). At the centrosome, TRIM37 is a key safeguard of mitotic fidelity: it ubiquitinates and limits Centrobin to prevent its condensation into ectopic, microtubule-nucleating centriolar assemblies, and it targets CEP192 for degradation while restraining PLK4 condensate-based ectopic spindle poles—activities that make TRIM37 levels (elevated by chr17q amplification) a determinant of sensitivity to PLK4 inhibition (PMID:32908304, PMID:33491649, PMID:33983387). TRIM37 also localizes to peroxisomal membranes in a PEX1/PEX5-dependent manner, where it ubiquitinates PEX5 at K464 to stabilize it and promote peroxisomal matrix protein import (PMID:11938494, PMID:28724525). In genotoxic stress signaling, ATM phosphorylates TRIM37 to drive its nuclear translocation, where it monoubiquitinates NEMO at K309 within a TRAF6-containing complex to trigger nuclear export of NEMO and IKK/NF-κB activation (PMID:30254148). TRIM37 further activates NF-κB through K63-linked ubiquitination of TRAF2 and TRAF6 (PMID:30043491, PMID:33839419), and positively regulates MTORC1 by enhancing the MTOR–RRAGB interaction and lysosomal MTOR localization, thereby suppressing TFEB-driven autophagy (PMID:29940807). Germline loss-of-function in TRIM37 causes mulibrey nanism, and Trim37-knockout mice recapitulate multi-organ disease features including infertility, cardiomyopathy, and metabolic abnormalities (PMID:11938494, PMID:27044324).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2002 High

    Established where TRIM37 acts in the cell and tied its localization to disease, showing peroxisomal targeting depends on the import machinery and is lost in a major disease mutation.

    Evidence Immunofluorescence colocalization and complementation in PEX1-/-, PEX5-/-, PEX7-/- fibroblasts, with disease-mutant constructs

    PMID:11938494

    Open questions at the time
    • Did not define the molecular activity of TRIM37 at peroxisomes
    • No substrate identified at this stage
  2. 2005 High

    Defined TRIM37 as a bona fide RING-dependent E3 ubiquitin ligase and showed disease mutations cripple its catalytic/folding properties, supplying the enzymatic basis for all later substrate work.

    Evidence Cell-free ubiquitination with GST-TRIM domain, RING mutagenesis (C35S;C36S), aggresome imaging, yeast two-hybrid

    PMID:15885686

    Open questions at the time
    • No physiological substrate identified
    • Autoubiquitination shown but chain linkage and cellular consequence undefined
  3. 2014 High

    Identified the first substrate-level chromatin function: TRIM37 monoubiquitinates H2A and partners with PRC1/PRC2 to silence tumor suppressors, explaining its oncogenic role in 17q23-amplified breast cancer.

    Evidence In vitro ubiquitination, genome-wide ChIP-chip, Co-IP, RNAi with transcriptional reactivation, xenografts

    PMID:25470042

    Open questions at the time
    • Mechanism of TRIM37 recruitment to specific promoters not resolved
    • Direct biochemical interaction with PRC2 subunits not fully mapped
  4. 2017 High

    Resolved how TRIM37 supports peroxisome function mechanistically: it ubiquitinates PEX5 at K464 to stabilize it and sustain matrix protein import, linking enzymatic activity to organelle homeostasis.

    Evidence Reciprocal Co-IP, site-directed mutagenesis (K464A, ΔCT51), import and protein-stability assays, apoptosis readouts

    PMID:28724525

    Open questions at the time
    • Ubiquitin chain type on PEX5 stabilization not fully characterized
    • Reconciliation with normal peroxisome morphology in Trim37-KO mice unexplained
  5. 2018 High

    Connected TRIM37 to genotoxic NF-κB signaling, showing ATM phosphorylation drives nuclear TRIM37 to monoubiquitinate NEMO at K309 and trigger IKK activation, defining a druggable node for chemosensitization.

    Evidence Co-IP, in vitro ubiquitination of NEMO K309, ATM kinase assay, TBM mutagenesis, TAT-TBM peptide, xenografts

    PMID:30254148

    Open questions at the time
    • Structural basis of TRAF6/NEMO complex assembly unresolved
    • Relationship to cytoplasmic TRAF-directed NF-κB activation not integrated
  6. 2018 Medium

    Extended TRIM37 into nutrient signaling, showing it enhances MTOR-RRAGB interaction and lysosomal MTOR localization to activate MTORC1 and suppress TFEB-driven autophagy.

    Evidence Co-IP (MTOR, RRAGB), immunofluorescence of lysosomal MTOR, TFEB phosphorylation blots, autophagy flux assays

    PMID:29940807

    Open questions at the time
    • Whether MTORC1 regulation requires TRIM37 ligase activity not established
    • No direct ubiquitination substrate in this axis identified
  7. 2018 Medium

    Broadened TRIM37's NF-κB role beyond NEMO by showing RING-dependent K63 ubiquitination of TRAF2 sustains pathway activation in lung cancer.

    Evidence Co-IP, ubiquitination assay, RING mutagenesis, NF-κB reporter, knockdown phenotypes

    PMID:30043491

    Open questions at the time
    • TRAF2 ubiquitination site not mapped
    • Single lab without reciprocal validation
  8. 2020 High

    Defined TRIM37 as a centrosomal gatekeeper whose levels dictate vulnerability to PLK4 inhibition by degrading CEP192 and restraining PLK4 condensates that drive acentrosomal mitosis.

    Evidence Two independent Nature studies: gain/loss-of-function with mitotic outcome assays, CEP192 degradation, PLK4 condensate and PCM foci imaging

    PMID:32908304 PMID:32908313

    Open questions at the time
    • Direct ubiquitination of CEP192 vs. indirect regulation not fully separated
    • Mechanism by which TRIM37 senses centrosome state unclear
  9. 2021 High

    Pinpointed Centrobin as the centrosomal substrate whose TRIM37-dependent ubiquitination controls solubility, preventing condensate-scaffolded ectopic spindle poles seen in patient cells.

    Evidence Two studies: TRIM37 KO/depletion, CLEM/SIM imaging, Co-IP and ubiquitination of Centrobin, PLK4/PLK1/Centrobin epistasis, patient-derived cells

    PMID:33491649 PMID:33983387

    Open questions at the time
    • Ubiquitin chain linkage on Centrobin not defined
    • Why only a subset of cells form ectopic poles unexplained
  10. 2020 Medium

    Linked TRIM37 H2A ubiquitination to DNA-repair-driven chemoresistance in TP53-mutant breast cancer via an ATM/E2F1/STAT feedback loop, with therapeutic targeting in vivo.

    Evidence RNAi, antisense-oligonucleotide nanoparticles, H2A ubiquitination assay, metastasis models, transcriptomics

    PMID:32855208

    Open questions at the time
    • Direct vs. indirect contribution of H2A ubiquitination to repair changes unresolved
    • Feedback loop wiring not fully dissected

Open questions

Synthesis pass · forward-looking unresolved questions
  • A wide array of additional reported substrates and signaling outputs (PTEN, P53, AP-2γ, Axin1, SMAD7, TRAF6) tie TRIM37 to Wnt/β-catenin, glycolysis, TGF-β and inflammatory programs across cancers, but it remains unresolved which represent direct, generalizable activities versus context-specific or low-confidence observations.
  • Many substrate claims rest on single-lab Co-IP/ubiquitination without reciprocal or structural validation
  • Ubiquitin chain types and modification sites largely unmapped
  • Unifying logic that selects among TRIM37's many substrates in a given cell is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 8 GO:0140096 catalytic activity, acting on a protein 6 GO:0016874 ligase activity 4 GO:0042393 histone binding 1
Localization
GO:0005815 microtubule organizing center 4 GO:0005777 peroxisome 2 GO:0005634 nucleus 1 GO:0005764 lysosome 1 GO:0005829 cytosol 1
Pathway
R-HSA-1640170 Cell Cycle 4 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 2 R-HSA-74160 Gene expression (Transcription) 1 R-HSA-9612973 Autophagy 1
Partners
CENTROBINCEP192MTORNEMOPEX5RRAGBTRAF2TRAF6
Complex memberships
PRC1/PRC2 (co-occupancy at target promoters)

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2014 TRIM37 functions as an E3 ubiquitin ligase that mono-ubiquitinates histone H2A (a chromatin modification associated with transcriptional repression). In 17q23-amplified breast cancer cells, TRIM37 associates with polycomb repressive complex 2 (PRC2), and together with PRC2 and PRC1 co-occupies target gene promoters to silence them. RNAi-mediated knockdown of TRIM37 results in loss of ubiquitinated H2A, dissociation of PRC1 and PRC2 from target promoters, and transcriptional reactivation of silenced genes including tumor suppressors. In vitro ubiquitin ligase assay, genome-wide ChIP-chip, RNA interference knockdown, co-immunoprecipitation, mouse xenograft tumor growth assay Nature High 25470042
2002 TRIM37 protein localizes to peroxisomes, as demonstrated by colocalization with peroxisomal markers in transfected cells and endogenous staining in HepG2 and intestinal smooth muscle cell lines. Peroxisomal localization requires PEX1 and PEX5 but not PEX7, as TRIM37 fails to import into peroxisomes in PEX1(-/-) and PEX5(-/-) mutant fibroblasts. A major Finnish disease-associated mutation abrogates peroxisomal localization, classifying mulibrey nanism as a peroxisomal disorder. Immunofluorescence colocalization with peroxisomal markers, transfection of mutant constructs, analysis in peroxin-deficient fibroblasts (PEX1-/-, PEX5-/-, PEX7-/- cells), immunohistochemistry American journal of human genetics High 11938494
2005 TRIM37 possesses RING-domain-dependent E3 ubiquitin ligase activity. Full-length TRIM37 and its TRIM domain undergo polyubiquitination when co-expressed with ubiquitin; bacterially produced GST-TRIM domain is polyubiquitinated in cell-free conditions. This activity is abolished by RING-domain mutation (Cys35Ser;Cys36Ser) and by the disease-associated missense mutation Leu76Pro. Ectopically expressed TRIM37 forms ubiquitin-, proteasome-, and chaperone-positive aggresomes; RING-mutant and patient-mutant proteins are markedly less prone to aggregation. Cell-free ubiquitination assay with bacterially produced GST-TRIM domain, co-expression with ubiquitin in cells, RING-domain mutagenesis (Cys35Ser;Cys36Ser), immunofluorescence analysis of aggresomes, yeast two-hybrid identification of ubiquitin as binding partner Experimental cell research High 15885686
2017 TRIM37 localizes to peroxisomal membranes and ubiquitylates PEX5 at lysine 464 (K464) by interacting with the C-terminal 51 amino acids (CT51) of PEX5. This ubiquitylation stabilizes PEX5 by preventing its proteasomal degradation, thereby promoting PTS protein import into peroxisomes. PEX5 mutations K464A or ΔCT51, or TRIM37 depletion/mutation, reduce PEX5 abundance and impair its cargo-binding and import functions. TRIM37 or PEX5 depletion induces apoptosis and enhances oxidative stress sensitivity. Co-immunoprecipitation, site-directed mutagenesis (K464A, ΔCT51), protein stability assay, peroxisomal import assay, RNAi knockdown, apoptosis assay, immunofluorescence localization The Journal of cell biology High 28724525
2018 TRIM37 interacts with MTOR and RRAGB proteins, enhances the MTOR-RRAGB interaction, and promotes lysosomal localization of MTOR, thereby activating amino acid-stimulated MTORC1 signaling. Loss of TRIM37 function reduces TFEB phosphorylation, causing TFEB nuclear translocation and transcriptional activation of lysosome biogenesis and autophagy genes. Enhanced autophagy upon TRIM37 loss depends on MTORC1 inhibition. Co-immunoprecipitation (TRIM37 with MTOR and RRAGB), immunofluorescence (lysosomal MTOR localization), western blotting (TFEB phosphorylation), RNAi knockdown, autophagy flux assays Autophagy Medium 29940807
2018 In response to genotoxic stress, ATM kinase phosphorylates TRIM37 in the cytoplasm, inducing its nuclear translocation. In the nucleus, TRIM37 forms a complex with NEMO and TRAF6 via a TRAF6-binding motif (TBM) and monoubiquitinates NEMO at K309, driving nuclear export of NEMO and subsequent IKK/NF-κB activation. A cell-penetrating TAT-TBM peptide that blocks this complex abrogates genotoxic NF-κB activation and sensitizes cancer cells to cisplatin. Co-immunoprecipitation, in vitro ubiquitination assay (monoubiquitination of NEMO K309), immunofluorescence (nuclear translocation), ATM kinase assay, TAT-TBM peptide inhibitor experiments, mutation of TRAF6-binding motif, xenograft in vivo experiments Cancer research High 30254148
2020 TRIM37 levels determine cellular vulnerability to PLK4 inhibition. High TRIM37 levels inhibit acentrosomal spindle assembly by promoting degradation of the centrosomal component CEP192, leading to mitotic failure when centrosomes are depleted. Low TRIM37 levels permit PLK4 to self-assemble into centrosome-independent condensates that serve as ectopic microtubule-organizing centres, enabling acentrosomal mitosis. Chr17q amplification (containing TRIM37) renders neuroblastoma and breast cancer cells highly sensitive to PLK4 inhibition. TRIM37 overexpression and knockdown with mitotic outcome assays, immunofluorescence, PLK4 inhibitor treatment, TRIM37-directed degradation of CEP192 assay, analysis of PLK4 condensate formation Nature High 32908304
2020 TRIM37 overexpression acts as a negative regulator of centrosomal pericentriolar material (PCM). In cells lacking centrosomes (after PLK4 inhibition), elevated TRIM37 blocks the formation of PCM foci that are required for acentrosomal spindle assembly and successful cell division. Overexpression of TRIM37 also delays centrosome maturation and separation at mitotic entry, increasing the frequency of mitotic errors and causing genomic instability. PLK4 inhibitor-induced centrosome depletion, TRIM37 overexpression/knockdown, immunofluorescence of PCM foci, mitotic timing assays, chromosome segregation analysis, live-cell imaging Nature High 32908313
2021 TRIM37 prevents the formation of centriolar protein assemblies (Cenpas) by regulating the stability and solubility of Centrobin. TRIM37 depletion causes Centrobin to accumulate in elongated entities that seed Cenpas formation; these Cenpas can act as microtubule-organizing centres. Cenpas formation upon TRIM37 depletion requires PLK4 and two parallel pathways relying on Centrobin and PLK1, respectively. TRIM37 interacts with and ubiquitinates Centrobin. Mulibrey patient-derived cells harbor these Centrobin condensate-organized ectopic poles. TRIM37 depletion, immunofluorescence, correlative light-electron microscopy, PLK4/PLK1/Centrobin epistasis analysis (double knockdown), Co-IP and ubiquitination assay of Centrobin, analysis of patient-derived cells eLife High 33491649
2021 TRIM37 prevents assembly of a centrobin-scaffolded structured condensate that buds off centrosomes and organizes ectopic spindle poles. In ~25% of TRIM37-deficient cells, the condensate recruits centrosomal proteins and acquires microtubule nucleation capacity during mitotic entry, causing transient multipolarity and multipolar segregation. Centrobin interacts with and is ubiquitinated by TRIM37. Removing Centrobin suppresses ectopic spindle pole formation and multipolar segregation in TRIM37-deficient cells. TRIM37 KO cell lines, live-cell imaging, immunofluorescence, structured illumination microscopy, Co-IP and ubiquitination assay (TRIM37-Centrobin), Centrobin knockdown epistasis, chromosome segregation assays, patient-derived cell analysis The Journal of cell biology High 33983387
2018 TRIM37 promotes K63-linked polyubiquitination of TRAF2, sustaining activation of the NF-κB pathway in non-small-cell lung cancer. Mutation of the RING finger domain of TRIM37 abolishes its ability to promote K63 polyubiquitination of TRAF2 and NF-κB activation. TRIM37 binds to TRAF2 as demonstrated by co-immunoprecipitation. Co-immunoprecipitation (TRIM37-TRAF2), in vitro/cellular ubiquitination assay, RING-domain mutagenesis, NF-κB luciferase reporter, overexpression and RNAi knockdown with apoptosis/proliferation readouts The Journal of pathology Medium 30043491
2020 TRIM37-directed histone H2A monoubiquitination enforces changes in DNA repair that render TP53-mutant triple-negative breast cancer cells resistant to chemotherapy. A positive feedback loop via ATM/E2F1/STAT signaling amplifies the TRIM37 network in chemoresistant cells. TRIM37 inhibition using antisense oligonucleotides conjugated to antifolate receptor 1 nanoparticles reduces lung metastasis in vivo. RNAi knockdown, TRIM37-specific antisense oligonucleotide nanoparticles, H2A ubiquitination assay, spontaneous metastatic murine models, transcriptomic analysis, ATM/E2F1/STAT pathway analysis Cancer research Medium 32855208
2020 TRIM37 mediates K48-linked ubiquitination and proteasomal degradation of PTEN, activating the AKT-GSK-3β-β-catenin signaling pathway in pancreatic cancer cells to sustain stemness and chemoresistance. Co-immunoprecipitation (TRIM37-PTEN), ubiquitination assay (K48-linked), protein stability assay, immunofluorescence, RNAi knockdown, mouse xenograft Frontiers in oncology Medium 33194618
2022 TRIM37 stimulates K63-chain-linked ubiquitination of the transcription factor AP-2γ, promoting AP-2γ translocation from the cytoplasm to the nucleus and facilitating AP-2γ chromatin binding and transcriptional activity in breast cancer cells. Proteomics/mass spectrometry to identify TRIM37-AP-2γ interaction, Co-immunoprecipitation, ubiquitination assay (K63-linked), immunofluorescence (AP-2γ localization), ChIP-seq (AP-2γ chromatin binding), RNAi knockdown with transcriptional readouts International journal of biological sciences Medium 35864973
2022 TRIM37 directly interacts with the tumor suppressor P53 protein and promotes its K48-linked ubiquitination and proteasomal degradation, thereby activating aerobic glycolysis and promoting hepatocellular carcinoma progression. Knockdown of P53 reverses the effects of TRIM37 knockdown on HCC cell growth and metastasis. Co-immunoprecipitation (TRIM37-P53), ubiquitination assay, protein stability assay, glycolysis assays (lactate, glucose, ATP), functional cell assays, P53 knockdown epistasis, mouse xenograft Experimental cell research Medium 36252649
2020 TRIM37 promotes K63-linked ubiquitination of TRAF6, facilitating NF-κB pathway activation. In the context of virus infection, TRIM37 positively regulates inflammatory responses; TRIM37 knockout reduces proinflammatory cytokine levels in bone marrow-derived macrophages and inhibits immune responses in H1N1-infected mice. Direct interaction between TRIM37 and TRAF6 was demonstrated by immunoprecipitation. Co-immunoprecipitation (TRIM37-TRAF6), K63 ubiquitination assay, TRIM37 knockout mice, ELISA (cytokines), flow cytometry, H&E staining, western blotting Biochemical and biophysical research communications Medium 33839419
2020 TRIM37 physically interacts with SMAD7 and promotes its ubiquitination-mediated proteasomal degradation, thereby enabling TGF-β signaling-dependent hepatic fibrosis. NF-κB activation mediated by ROS is necessary for transcriptional induction of TRIM37 during HBV infection. Co-immunoprecipitation (TRIM37-SMAD7), ubiquitination/degradation assay, RNAi knockdown, mouse fibrosis model, NF-κB reporter, ROS inhibitor treatment Molecular therapy. Nucleic acids Medium 32916597
2023 TRIM37 promotes Wnt/β-catenin signaling in gallbladder cancer by ubiquitinating Axin1, leading to Axin1 degradation and subsequent β-catenin stabilization and activation. Co-immunoprecipitation (TRIM37-Axin1), ubiquitination assay, protein stability assay, RNAi knockdown, in vitro and in vivo functional assays Translational oncology Low 37379772
2023 TRIM37 directly interacts with TRAF6 and promotes K63-linked ubiquitination of TRAF6, leading to IKKβ phosphorylation. Additionally, TRIM37 enhances translocation of IKKγ (NEMO) from the nucleus to the cytoplasm, stabilizing the cytoplasmic IKK complex and prolonging NF-κB-driven inflammation during hepatic ischemia/reperfusion injury. Co-immunoprecipitation (TRIM37-TRAF6), immunofluorescence (IKKγ translocation), western blotting (subcellular fractionation), IKK inhibitor rescue experiments, in vivo 70% hepatic I/R model Molecular medicine (Cambridge, Mass.) Medium 37158850
2021 During PM-induced autophagy in lung epithelial cells, TRIM37 is itself degraded via autophagy. This degradation of TRIM37 protects TRAF6 from proteasomal degradation, increasing TRAF6 levels and thereby driving NF-κB-dependent chemokine production that recruits neutrophils and promotes pre-metastatic niche formation. RNAi knockdown of TRIM37 and TRAF6, autophagy inhibition (hydroxychloroquine), ROS blockade, immunofluorescence, in vitro and in vivo lung metastasis models Autophagy Medium 34524943
2016 Trim37 knockout mice recapitulate several features of human mulibrey nanism including infertility (germ cell aplasia, Leydig cell hyperplasia, lipid accumulation), elevated FSH/LH, elevated fasting blood glucose, non-compaction cardiomyopathy, hepatomegaly, fatty liver, and tumor formation. Liver peroxisome amount and morphology appeared normal in Trim37-/- mice. Trim37 knockout mouse model, CT scan (skeletal parameters), histology, hormone assays, glucose/insulin measurements, autopsy/tumor analysis, electron microscopy of peroxisomes Biology open Medium 27044324
2006 TRIM37 mutations affecting the B-box domain (p.Cys109Ser) and the TRAF domain (p.Glu271_Ser287del in-frame deletion) both alter the subcellular localization of TRIM37, suggesting that both the B-box and TRAF domains are important for TRIM37 protein-protein interactions and proper peroxisomal targeting. Immunofluorescence of transfected mutant constructs to assess subcellular localization Clinical genetics Low 17100991
2015 TRIM37 activates Wnt/β-catenin signaling in hepatocellular carcinoma by interacting with β-catenin and activating the transcriptional activity of the β-catenin/TCF complex, as well as expression of downstream target genes. This activation promotes EMT, cell migration, and metastasis. Co-immunoprecipitation (TRIM37-β-catenin), dual-luciferase reporter assay (β-catenin/TCF transcriptional activity), RNAi knockdown and overexpression, in vivo metastasis assay Biochemical and biophysical research communications Low 26208456
2020 PBK kinase directly interacts with TRIM37 and promotes its phosphorylation and nuclear translocation, which subsequently activates the NF-κB pathway to confer olaparib (PARP inhibitor) resistance in ovarian cancer cells. Co-immunoprecipitation (PBK-TRIM37), immunofluorescence (nuclear translocation), PBK inhibitor treatment, RNAi knockdown, in vitro and in vivo resistance assays Experimental & molecular medicine Low 35859118
2020 ASB16-AS1 lncRNA cooperates with ATM serine/threonine kinase to induce TRIM37 phosphorylation (post-translational modification), activating the NF-κB pathway in gastric cancer cells. Co-immunoprecipitation, RNA immunoprecipitation (RIP), luciferase reporter assay, pulldown assay Gastric cancer Low 32572790
2021 TRIM37 orchestrates TGF-β1 signaling activation in renal cell carcinoma through direct mediation of histone H2A ubiquitination modifications, thereby promoting EMT and malignant progression. RNAi knockdown and overexpression, ubiquitination assay (H2A), TGF-β1 pathway analysis, interactive network analysis, in vitro and in vivo functional assays Journal of experimental & clinical cancer research Low 34130705

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1982 A simple, rapid method for the determination of glucose, lactate, pyruvate, alanine, 3-hydroxybutyrate and acetoacetate on a single 20-mul blood sample. Clinica chimica acta; international journal of clinical chemistry 297 7105409
2014 TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. Nature 149 25470042
2020 TRIM37 controls cancer-specific vulnerability to PLK4 inhibition. Nature 124 32908304
1984 Nucleotide sequence of the maize transposable element Mul. Nucleic acids research 97 6089104
2020 Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. Nature 95 32908313
2013 Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 81 23315315
2003 Expression and regulation of L-cystine transporter, system xc-, in the newly developed rat retinal Müller cell line (TR-MUL). Glia 72 12898700
2017 TRIM37, a novel E3 ligase for PEX5-mediated peroxisomal matrix protein import. The Journal of cell biology 67 28724525
2005 TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase. Experimental cell research 67 15885686
2017 Gene-Tree Reconciliation with MUL-Trees to Resolve Polyploidy Events. Systematic biology 65 28419377
2011 TRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions. Current pharmaceutical biotechnology 64 20932259
2015 Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Biochemical and biophysical research communications 63 26208456
2002 The TRIM37 gene encodes a peroxisomal RING-B-box-coiled-coil protein: classification of mulibrey nanism as a new peroxisomal disorder. American journal of human genetics 58 11938494
2019 LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. Oncogene 57 31409898
2018 TRIMming down to TRIM37: Relevance to Inflammation, Cardiovascular Disorders, and Cancer in MULIBREY Nanism. International journal of molecular sciences 54 30586926
2020 ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 53 32572790
2012 HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52 22423133
2011 A μL-scale micromachined microbial fuel cell having high power density. Lab on a chip 49 21311808
2019 Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 47 30020446
2018 Knockdown of TRIM37 suppresses the proliferation, migration and invasion of glioma cells through the inactivation of PI3K/Akt signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 46 29324313
2018 Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway. The Journal of pathology 46 30043491
2017 Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. The lancet. HIV 46 28063815
2016 Characterization and Functional Analysis of 4-Coumarate:CoA Ligase Genes in Mul-berry. PloS one 45 27213624
2018 Mulberrin (Mul) reduces spinal cord injury (SCI)-induced apoptosis, inflammation and oxidative stress in rats via miroRNA-337 by targeting Nrf-2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 41 30257365
2015 Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PloS one 41 26020949
2018 Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl. AIDS (London, England) 39 29683843
2018 TRIM37 deficiency induces autophagy through deregulating the MTORC1-TFEB axis. Autophagy 39 29940807
2017 TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancer. Molecular medicine reports 38 28098873
2018 An ATM/TRIM37/NEMO Axis Counteracts Genotoxicity by Activating Nuclear-to-Cytoplasmic NF-κB Signaling. Cancer research 36 30254148
2021 Circular RNA circRNA_101996 promoted cervical cancer development by regulating miR-1236-3p/TRIM37 axis. The Kaohsiung journal of medical sciences 33 33728810
2015 TRIM37 promoted the growth and migration of the pancreatic cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 33 26395261
2015 Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV medicine 32 25711330
2018 BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA. Analytical chemistry 31 29498256
2011 Regulation of glutamate metabolism by hydrocortisone and branched chain keto acids in cultured rat retinal Müller cells (TR-MUL). Neurochemistry international 31 21756956
2010 A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. The Journal of infectious diseases 31 20942650
2004 Novel mutations in the TRIM37 gene in Mulibrey Nanism. Human mutation 31 15108285
2021 TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner. Journal of experimental & clinical cancer research : CR 30 34130705
2012 Estimating malaria parasite density: assumed white blood cell count of 10,000/μl of blood is appropriate measure in Central Ghana. Malaria journal 30 22823983
1998 Cytotoxic principles of a Bangladeshi crude drug, akond mul (roots of Calotropis gigantea L.). Chemical & pharmaceutical bulletin 30 9549894
2020 Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer. Cancer research 29 32855208
2018 TRIM37 inhibits PDGF-BB-induced proliferation and migration of airway smooth muscle cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 29 29477054
2014 Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda. AIDS (London, England) 29 25022596
2005 Insulin resistance syndrome in subjects with mutated RING finger protein TRIM37. Diabetes 29 16306379
2010 Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl. AIDS (London, England) 28 20852403
2022 PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer. Experimental & molecular medicine 27 35859118
2021 TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin. eLife 27 33491649
2012 Vertically grown multiwalled carbon nanotube anode and nickel silicide integrated high performance microsized (1.25 μL) microbial fuel cell. Nano letters 27 22268850
2020 ROS/NF-κB Signaling Pathway-Mediated Transcriptional Activation of TRIM37 Promotes HBV-Associated Hepatic Fibrosis. Molecular therapy. Nucleic acids 26 32916597
2012 The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 26 22955429
2015 Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial. PloS one 24 25966339
2021 Increased alveolar epithelial TRAF6 via autophagy-dependent TRIM37 degradation mediates particulate matter-induced lung metastasis. Autophagy 23 34524943
2006 Wilms' tumor and novel TRIM37 mutations in an Australian patient with mulibrey nanism. Clinical genetics 23 17100991
2021 TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway. International journal of clinical oncology 22 33387087
2020 TRIM37 Mediates Chemoresistance and Maintenance of Stemness in Pancreatic Cancer Cells via Ubiquitination of PTEN and Activation of the AKT-GSK-3β-β-Catenin Signaling Pathway. Frontiers in oncology 22 33194618
2023 Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer. Journal of medicinal chemistry 21 37279162
2018 TRIM37 promotes cell invasion and metastasis by regulating SIP1-mediated epithelial-mesenchymal transition in gastric cancer. OncoTargets and therapy 21 30573971
2017 TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. Oncology letters 21 29163677
2016 Trim37-deficient mice recapitulate several features of the multi-organ disorder Mulibrey nanism. Biology open 21 27044324
2012 Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. AIDS (London, England) 21 22441247
2017 Knockdown of Tripartite Motif-Containing Protein 37 (TRIM37) Inhibits the Proliferation and Tumorigenesis in Colorectal Cancer Cells. Oncology research 20 28081740
2015 Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative. BMC health services research 20 26108273
2015 High throughput cryopreservation of cells by rapid freezing of sub-μl drops using inkjet printing--cryoprinting. Lab on a chip 20 26190571
2010 Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. HIV medicine 20 20659176
2008 Dehydroascorbic acid uptake and intracellular ascorbic acid accumulation in cultured Müller glial cells (TR-MUL). Neurochemistry international 20 18353508
2003 A novel splice site mutation in the TRIM37 gene causes mulibrey nanism in a Turkish family with phenotypic heterogeneity. Human mutation 20 12754710
2021 TRIM37 prevents formation of condensate-organized ectopic spindle poles to ensure mitotic fidelity. The Journal of cell biology 19 33983387
2018 TRIM37 targets AKT in the growth of lung cancer cells. OncoTargets and therapy 19 30510432
2022 Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. European journal of medicinal chemistry 18 35576702
2021 Long non-coding RNA TMPO-AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR-1179/TRIM37 axis. Oncology letters 18 33981362
2020 TRIM37 is highly expressed during mitosis in CHON-002 chondrocytes cell line and is regulated by miR-223. Bone 18 32353567
2020 LncRNA NEAT1 acts as a key regulator of cell apoptosis and inflammatory response by the miR-944/TRIM37 axis in acute lung injury. Journal of pharmacological sciences 18 33451755
2014 Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? AIDS patient care and STDs 18 24833016
2011 Shear-mediated platelet adhesion analysis in less than 100 μl of blood: toward a POC platelet diagnostic. IEEE transactions on bio-medical engineering 18 21342809
2022 Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37. Experimental cell research 17 36252649
2021 TRIM37 negatively regulates inflammatory responses induced by virus infection via controlling TRAF6 ubiquitination. Biochemical and biophysical research communications 17 33839419
2006 Tissue expression of the mulibrey nanism-associated Trim37 protein in embryonic and adult mouse tissues. Histochemistry and cell biology 17 16514549
2021 miR-942-5p prevents sepsis-induced acute lung injury via targeting TRIM37. International journal of experimental pathology 16 34716956
2020 Mul-tiomics analysis of cadmium stress on the ovarian function of the wolf spider Pardosa pseudoannulata. Chemosphere 16 32014633
2016 Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. PLoS neglected tropical diseases 16 26849213
2014 Assumed white blood cell count of 8,000 cells/μL overestimates malaria parasite density in the Brazilian Amazon. PloS one 16 24721983
2009 Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 16 19329943
2008 Transcription enhancer factor 3 (TEF3) mediates the expression of Down syndrome candidate region 1 isoform 1 (DSCR1-1L) in endothelial cells. The Journal of biological chemistry 16 18840614
2021 TRIM37: a critical orchestrator of centrosome function. Cell cycle (Georgetown, Tex.) 15 34672905
2022 Mul-SNO: A Novel Prediction Tool for S-Nitrosylation Sites Based on Deep Learning Methods. IEEE journal of biomedical and health informatics 14 34762593
2020 The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis. BMC infectious diseases 14 32532212
2017 Focusing analytes from 50 μL into 500 pL: On-chip focusing from large sample volumes using isotachophoresis. Scientific reports 14 28874694
2015 Identification of the Mycobacterium ulcerans protein MUL_3720 as a promising target for the development of a diagnostic test for Buruli ulcer. PLoS neglected tropical diseases 14 25668636
2023 TRIM37 exacerbates hepatic ischemia/reperfusion injury by facilitating IKKγ translocation. Molecular medicine (Cambridge, Mass.) 13 37158850
2022 TRIM37 Augments AP-2γ Transcriptional Activity and Cellular Localization via K63-linked Ubiquitination to Drive Breast Cancer Progression. International journal of biological sciences 13 35864973
2020 Ginkgolide B protects human pulmonary alveolar epithelial A549 cells from lipopolysaccharide-induced inflammatory responses by reducing TRIM37-mediated NF-κB activation. Biotechnology and applied biochemistry 13 31691373
2019 Is it Safe and Cost Saving to Defer the CD4+ Cell Count Monitoring in Stable Patients on Art with More than 350 or 500 cells/μl? Mediterranean journal of hematology and infectious diseases 13 31700588
2015 In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria. Antimicrobial resistance and infection control 13 26550474
2013 Refractory congestive heart failure following delayed pericardectomy in a 12-year-old child with Mulibrey nanism due to a novel mutation in TRIM37. European journal of pediatrics 13 23385855
2005 Characterisation of the mulibrey nanism-associated TRIM37 gene: transcription initiation, promoter region and alternative splicing. Gene 13 16310976
2023 TRIM37 promotes gallbladder cancer proliferation by activating the Wnt/β-catenin pathway via ubiquitination of Axin1. Translational oncology 12 37379772
2018 Cryptococcal antigen positivity combined with the percentage of HIV-seropositive samples with CD4 counts <100 cells/μl identifies districts in South Africa with advanced burden of disease. PloS one 12 29894509
2012 Innate immune genes including a mucin-like gene, mul-1, induced by ionizing radiation in Caenorhabditis elegans. Radiation research 12 22967128
2011 A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL. The Journal of infectious diseases 12 21849285
2001 Expression of MUL, a gene encoding a novel RBCC family ring-finger protein, in human and mouse embryogenesis. Mechanisms of development 12 11578880
2021 TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer. Journal of Cancer 11 33391428

Missed literature

Know a paper Affinage missed for TRIM37? Flag it for the maintainers and the community.

No submissions yet.